Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

GigaMune, Inc. is a company headquartered in San Francisco, CA. The firm develops cell therapies for tumors. David S. Johnson is currently the CEO of the company.\nThe company says this about itself: GigaMune Inc. is a cancer cell therapy company focused on T cell receptor (TCR) discovery and development, founded in 2017 as a spin-out from GigaGen. GigaMune's patented TCR technologies facilitate discovery of rare TCRs from the immune repertoires of patients with exceptional response to cancer. GigaMune's research efforts benefit from a strategic partnership with Massachusetts General Hospital and Harvard Medical School. GigaMune is located in South San Francisco, California.

Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL.

Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

Shanghai Ruotai Pharmaceutical Technology Co., Ltd., established on 2017-07-11, Business scope includes technology development in the field of biomedical technology,technical consulting,technology transfer,Technical Services,Biological reagents for non-clinical diagnosis,Pharmaceutical research and development,R&D of medical devices,Medical device management,Instrumentation,food additives,Sales of Electronics,food circulation,business inquiries,Business Management Consulting,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Suzhou Ruotai Pharmaceutical Technology Co., Ltd., established on 2016-12-07, Business scope includes technology development in the field of medicine and biology,Technical Services,technology transfer,technical consulting;research and development,Sales:Pharmaceutical Intermediates.Engaged in the import and export business of the above technologies and products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA.

Viagene is a life science business that was started by researchers with a wealth of knowledge in the biological sciences. It is dedicated to achieving its business objective of contributing to the advancement of molecular and cell biology research across the globe by offering creative, practical, and accessible products and services. The company's main goal is to provide inventive methods and new goods to advance life science research.

CDR-Life Inc. is a company headquartered in Schlieren, Switzerland. The firm operates as a biotherapeutics company. It was founded in 2017 by Dominik Escher, Leonardo Borras, Christian Leisner, Konstantin von Schulthess and Rouven Bingel-Erlenmeyer. Christian Leisner has been the CEO since the company founding.\nThe company says this about itself: CDR-Life is a privately held, biotherapeutics company leveraging its unique antibody technology, M-gager®, to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC). CDR-Life is advancing a robust pipeline of novel fully cancer-directed T-cell engagers in various solid tumors. The team behind CDR-Life has extensive experience in all key areas of biologics development, hold numerous patents, and has previously invented new marketed medicines. CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide.

Board of Regents of The University of Oklahoma is a private company headquartered in Norman, OK, with domestic subsidiaries, specializing in radio broadcasting stations.

The Institute for Biomathematics and Biometry conducts fundamental research in areas including Epidemiology, Analysis of Complex Experimental Data, Analysis of Environmental Chemicals, Machine Learning, Bacterial Communication Processes in the Rhizosphere, the Regulation Pathway of NF-κB and Coagulation Cascades.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Henan Genetic Resources Cell Bank Co., Ltd., established on 2019-07-24, Business scope includes stem cell technology development and application;stem cell,Collection and storage of immune cells and development of related technologies,consult;Bioengineering technology development,consult,comminicate,transfer,Promotion service;Engaged in technology development in the field of medicine;Nutrition and Health Consulting;Sales:Healthy food,Instrumentation,Laboratory equipment and consumables,other chemical products,Class I medical device,Class II medical device,Class III Medical Devices,Daily necessities,cosmetic,electronic product.Involved in licensing projects,It should be operated after obtaining the permission of the relevant department

Active Biotech AB engages in the development of pharmaceutical products. The firm specializes in the medical areas where the immune defense is of significant importance, including neurodegenerative diseases, autoimmune, inflammatory disease, and various forms of cancer. Its portfolio comprises orally active immunomodulatory molecules as well as antibody-based immunotherapy. The company was founded on June 15, 1982 and is headquartered in Lund, Sweden.

Tianjin Merit Medical Technology Co., Ltd., established on 2018-07-03, Business scope includes biological reagents,Reagent test kit,Medical product development,Production,Sales and related technical consultation,Serve,transfer;Engage in import and export business permitted by national laws and regulations;Conference Services,Exhibition display service;Instrumentation,Medical device research and development,Production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

MorphoSys AG is a therapeutic antibody company based in Martinsried, Germany. The company claims to have more than 100 drugs in its wider pipeline, being investigated for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also maintains an internal pipeline with antibodies in preclinical and clinical development.